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Background: Virus rescue from transfected cells is an extremely useful technique that allows defined viral clones
to be engineered for the purpose of rational vaccine design or fundamental reverse genetics studies. However,
it is often hindered by low primary rescue success rates or yields, especially with field-derived viral strains.
Approach: We investigated the possibility of enhancing influenza virus rescue by eliciting cell fusion to increase
the chances of having all necessary plasmids expressed within the same polykaryon. To this end we used the
Maedi-Visna Virus envelope protein which has potent fusion activity in cells from a wide range of different species.
Results: Co-transfecting cells with the eight plasmids necessary to rescue influenza virus plus a plasmid expressing
the Maedi-Visna Virus envelope protein resulted in increased rescue efficiency. In addition, partial complements of
the 8-plasmid rescue system could be transfected into two separate populations of cells, which upon fusion led to
live virus rescue.
Conclusion: The simple modification described here has the potential to improve the efficiency of the virus rescue
process and expand the potential applications for reverse genetic studies.
Keywords: Influenza, Virus rescue, Cell fusion, Reverse geneticsBackground
Influenza is a contagious disease that represents a se-
rious health threat to humans and other animals world-
wide. Influenza A viruses, in particular, can infect a
variety of species. A global reservoir for these viruses
exists in wild waterfowl and shorebirds, from which
novel viruses can emerge to infect mammalian species.
Influenza is therefore a potential threat to humans, pigs,
horses, sea mammals, ferrets, mink as well as many te-
rrestrial bird species [1]. In the past decades, several dra-
matic episodes of large-scale mortality have occurred in
domestic birds, humans, and other species. To date, the
main approach to control influenza epidemics and pan-
demics in human and other animal populations is
through vaccination (reviewed in [2]) and biosecurity, al-
though other approaches may help prevent the transmi-
ssion of highly pathogenic influenza in some species [3].* Correspondence: v.bourret@envt.fr
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reproduction in any medium, provided the orStrategies for regenerating RNA viral genomes from
plasmid DNA clones (“virus rescue”) have enabled the
powerful technique of reverse genetics to be applied to
many different RNA viruses including, among others,
influenza, rabies, Coronavirus, Rift Valley fever virus or
fish RNA viruses [4-8]. This technique allows clonal
virus stocks with a defined genotype to be engineered. It
therefore has major medical applications as it enables
vaccines to be rationally designed by inserting attenuat-
ing mutations or chosen antigens into a defined viral
background, enhancing our control options for patho-
gens such as influenza virus [9-15]. In fundamental virus
studies, it also enables researchers to test the conse-
quences of defined genetic differences on phenotype,
such as growth properties, cell-virus interaction, replica-
tion cycle characteristics, pathogenicity, or others - the
approach known as “reverse genetics”. Various solutions
have been developed for satisfying the requirements for
the transcribed RNAs to become infectious when pro-
duced inside a permissive cell. Among the most complex
and demanding systems is that required for theLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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enza virus.
The basic strategy for the most commonly used influ-
enza virus rescue systems comprises a set of plasmids
that each drives the expression of one viral genome-
sense transcript corresponding to each of the eight viral
segments. Accurately tailored 5' and 3' termini are
achieved by positioning RNA Polymerase I (Pol I) tran-
scription initiation and termination sites respectively (or
by using the Hepatitis Delta virus ribozyme to cleave the
correct 3' end). Because the RNA is negative sense, the
virus polymerase must be produced before replication
can ensue. This can be achieved by co-transfecting a fur-
ther four plasmids that produce the replication proteins
(PB2, PB1, PA, NP) in the so-called “12-plasmid system”
[16,17]. A derivative of this system uses tandem oppos-
ing RNA Pol I and Cytomegalovirus (CMV) promoters
to drive expression of viral genome RNAs and mRNAs
respectively encoding all the viral proteins, commonly
referred to as the “8-plasmid system” [18,19]. Another
development has been the production of vectors carry-
ing multiple genome segment expression cassettes [20].
These strategies can be effective and have proven very
useful for a number of purposes. However regenerating
field strains and some mutants and reassortants is often
less efficient than for well-adapted laboratory strains and
it is not uncommon for several attempts to be needed
before a particular viral construct is successfully rescued.
This suggests the existence of one or more limiting fac-
tors in the process and prompted us to test whether
some of these could be overcome to increase rescue
efficiency. Several factors may impact virus rescue effi-
ciency. Examples include the replicative ability of a field-
derived avian virus in mammalian cells or the balance of
the virus’ haemagglutinin and neuraminidase activities
[21]. We hypothesized that one limitation might be the
ability to successfully transfect and simultaneously
express eight different plasmids within an individual cell.
We therefore reasoned that cell fusion might maximize
the likelihood of all eight influenza gene-bearing plas-
mids being present in the same polykaryon and thereby
enhance rescue efficiency.
The Maedi-Visna virus (MVV) is a Lentivirus causing
chronic pneumonia or a progressive demyelinating dis-
ease in sheep. Its envelop glycoprotein (hereafter referred
to as Env) is a major target for virus neutralization and
can cause substantial host cell fusion. Receptor to this
protein has not yet been identified but is known to be
expressed on cells from a wide range of species including
primates, avians and rodents [22]. We therefore exam-
ined co-transfecting an Env expression vector along with
the eight plasmid rescue system into HEK 293T/17 cells
to determine its effect on virus rescue efficiency
(Figure 1).Results
Cell fusion with the Maedi-Visna virus envelope protein
(Env) in 293 T
Additional file 1 (Video 1) and Additional file 2 (Video
2) show 293 T cells transfected with 0.4 μg of a Green
Fluorescent Protein(GFP)-expressing plasmid plus 0.4 μg
of an inert plamid (Video 1), or 0.4 μg of the GFP plas-
mid plus 0.4 μg of the Env-expressing plasmid (Video 2).
Cells were kept in FCS-containing medium for the
whole duration of the footage. The video shows a
marked fusion process, including visible cell-to-cell GFP
transfer, in cells transfected with the Env plasmid, while
cells keep dividing over time (Additional file 1: Video 1
and Additional file 2: Video 2).
Enhanced yields with the Maedi-Visna virus envelope
protein (Env)
For virus rescues, we initially worked with a fixed total
mass of 0.8 μg of DNA per well in a 24-well plate format,
which had previously been determined to be the optimal
amount of DNA for best transfection efficiency in our
lab. We varied the proportion of viral genes-containing
(hereafter “viral rescue” plasmids) and Env-expressing
(or an inert control named B1) plasmids comprising the
0.8 μg total in 0.2 μg (25%) increments. Results of this ti-
tration for the lab-adapted strain A/Puerto Rico/8/34
(hereafter PR8) are shown in Figure 2. Transfecting
0.8 μg of the viral rescue plasmids alone resulted in an
average yield of 4.0x103 ± 1.8x103 (SD) plaque forming
units (p.f.u.) per millilitre. Reducing the amount of viral
rescue plasmids by replacing them proportionately with
the B1 control plasmid exhibited an initial plateau but
reduced the yield sharply at the 0.2 μg level. Co-
transfecting the Env plasmid tended to increase the yield
at all levels and had a particularly marked effect when the
viral rescue plasmids were limiting (e.g. producing
8.2x103 ± 3.1x103 (SD) p.f.u./mL when as little as 0.2 μg
viral rescue plasmids were included; t4 =−4.63, p = 0.0098).
Increasing the proportion of viral rescue plasmids while
decreasing the proportion of Env-expressing plasmid gave
higher yields until an apparent optimum was reached for
0.2 μg (25%) of Env-expressing plasmid and 0.6 μg (75%)
of viral rescue plasmids. Dispersion of rescue yield values
was however generally high and statistical significance was
not detected for the differences observed at the 0.4 μg and
0.6 μg levels.
Application to the rescue of a strain derived from a field
sample
We tested whether using the Env-expressing plasmid in
the proportions determined above would enhance the
practical rescue of a viral strain derived from a low patho-
genicity avian influenza (LPAI) field sample (A/mallard/
Netherlands/10/99). Such strains are usually more
Figure 1 Principle of the fusion approach applied to the influenza A 8-plasmid rescue system. The eight virus rescue plasmids are
transfected in 293 T cells together with the Env expressing plamsid. Our hypothesis is that individual 293 T cells tend to be transfected with
partial complements of the viral rescue plasmids. Upon fusion, all eight necessary viral rescue plasmids can be expressed in one syncytium,
allowing rescue of complete virions.
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as PR8, giving low yields or failing to rescue in all attempts.
In this experiment, Lipofectamine LTX (Invitrogen) was
used instead of FuGene 6 (Roche) as transfection reagent
as the latter had been discontinued by the manufacturer.Figure 2 Yield of rescued PR8 virus obtained using different
plasmid proportions. The total amount of plasmid transfected per
well was set to 0.8 μg in a 24-well plate format for the whole
experiment. A proportion of this amount was dedicated to the viral
rescue plasmids, while the rest of the amount was dedicated either
to the Env-expressing plasmid (black symbols) or the B1 inert
plasmid (grey symbols), referred to as "other plasmids" in the chart.
Each point shows the average yield from three replicate
transfections and error bars indicate standard deviation. Negative
results (0 p.f.u./mL) are plotted as 1 p.f.u./mL on the logarithmic
scale. **, p < 0.01 at the 0.2 μg level.Figure 3 shows the comparison of yields when using 100%
of viral rescue plasmids versus using 75% of viral rescue
plasmids plus 25% of Env-expressing plasmid. This experi-
ment showed an average yield increase of between one
and two log in 6-well plates (p= 0.019) and in 24-well
plates (p= 0.002) when using fusion. A 0.8 μg total DNA
mass was used per well in 24-well plates whereas a 4 μg
total DNA mass was used per well in 6-well plates. In
6-well plates, one out of three replicates where fusion
was not used was negative (i.e. gave no p.f.u.).Fusion rescue of incomplete combinations of viral
segments
To test whether virus could be rescued from cells con-
taining incomplete complements of viral segments by fus-
ing with cells carrying the missing components, we
transfected cells in separate batches with partial comple-
ments of PR8 rescue plasmids and then co-cultured them.
In an experiment named “4+ 4”, 0.15 μg of each one of
segments 1, 2, 3, and 5 as well as 0.2 μg of either B1 or
Env-expressing plasmids were transfected into one batch
of cells, and identical amounts of segments 4, 6, 7, and 8
as well as 0.2 μg of either B1 or Env-expressing plasmids
were transfected into another batch of cells. In another ex-
periment named “7+1”, 0.086 μg of each one of segments
1, 3, 4, 5, 6, 7, and 8 as well as 0.2 μg of either B1 or
Env-expressing plasmids were transfected into one batch
of cells, and 0.086 μg of segment 2 as well as 0.714 μg of
either B1 or Env-expressing plasmids were transfected
into another batch of cells. On the day after transfection,
Table 1 Yields (in p.f.u./mL) from cells transfected with
partial complements of the eight PR8 rescue plasmids
"4+4"1 "7+1"1
with B12 with Env2 with B12 with Env2
Repeat 1 0 5000 0 1400
Repeat 2 0 390 10 50
Repeat 3 0 110 0 150
This table shows the viral yields (p.f.u./mL) from cells transfected with the
eight PR8 rescue plasmids split into separate batches at the time of
transfection and brought together on the next day.
1 In the "4 + 4" experiment, one batch of cells was transfected with plasmids
encoding segments 1, 2, 3, 5, while a complementary batch of cells was
transfected with plasmids encoding segments 4, 6, 7, 8. In the "7 + 1"
experiment, one batch was transfected with plasmids encoding segments 1, 3,
4, 5, 6, 7, 8 and the complementary batch was transfected with segment 2.
The cells from complementary batches were dislodged and brought together
at day 1 post transfection. These experiments consisted of triplicate
transfections for each condition (Repeats 1 to 3).
2 In addition to the transfection with influenza plasmids, cells were transfected
with either the Env-expressing or the empty B1 plasmid.
Figure 4 Effect of adding Env-expressing or inert plasmid
beyond 0.8 μg total DNA on primary rescue yields. This figure
shows the effect of adding increasing amounts of Env-expressing or
inert B1 plasmid to a fixed amount of 0.6 μg of PR8 rescue plasmids
on primary rescue efficiency in a 24-well plate format. Each point
shows the average yield from three replicate transfections and error
bars indicate standard deviation.
 
Figure 3 Effect of using the MVV Env on recovered virus yield
of a field-derived LPAI strain. This figure shows the effect of
substituting 25% of the viral genes containing plasmids for the MVV
envelope gene-containing plasmid on the rescue efficiency of a low
pathogenicity avian influenza strain derived from a field sample. The total
amount of transfected DNA is 4 μg per well in 6 well plates and 0.8 μg
per well in 24 well plates. The average of three replicates is shown and
error bars indicate standard deviation. Asterisks indicate levels of
statistical significance as follows: *, p<0.05; **, p<0.01. wp, well plate.
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and then pooled, and on day 3 treated with trypsin. Infec-
tious yields were assessed by plaque formation assay.
Table 1 shows successful rescue of live virus in all
attempts where cells transfected separately with com-
plementary sets of influenza rescue plasmids were
allowed to fuse together at day 1 post transfection.
No live virus was recovered when the empty B1 plas-
mid was used instead of the Env-expressing plasmid,
except for one 100 μL aliquot from the “7 + 1” experi-
ment which yielded one p.f.u.
Addition of extra Env-expressing plasmid
We tested whether adding Env-expressing plasmid beyond
a total amount of DNA of 0.8 μg per well in a 24-well
plate would be detrimental or beneficial to the rescue.
Figure 4 shows the result of a titration where a fixed
amount of 0.6 μg of PR8 rescue plasmids was used in
addition to which Env-expressing plasmid was added in
quantities varying from 0.2 μg to 0.8 μg. The total amount
of DNA transfected was therefore 0.8 μg to 1.4 μg per
well. Transfection reagent was adjusted to maintain the
appropriate ratio to DNA quantity. In order to look solely
at primary yield, trypsin was not added during this rescue
and viruses were harvested at day 3 post transfection.
This experiment confirmed that in the absence of fu-
sion, adding DNA beyond 0.8 μg per well is detrimental
to the rescue, as shown by decreasing yields when adding
increasing amounts of the inert plasmid B1, probably dueto toxicity or origin competition. However, adding Env-
expressing plasmid to PR8 rescue plasmids beyond a total
of 0.8 μg of DNA per well gave a modest increase in yields,
with a maximum for 0.4 μg of Env-expressing plasmid
added to 0.6 μg of PR8 rescue plasmids.
Discussion
Increased rescue efficiency with the Env-expressing plasmid
Virus rescue has major applications in the rational de-
sign of influenza A vaccines [12,15,23-25], which are to
date the main control options in use against this disease.
It is also a powerful technique in fundamental research on
influenza A, B and C [4,26-28] and many other RNA
viruses [29]. It is useful in this context to enhance the
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a variety of gene combinations. This report shows that cell
fusion mediated by the Maedi-Visna virus envelope protein
can be an effective tool in overcoming the challenge of
having eight different plasmids expressed together in a
single cell for the purpose of influenza A virus rescue.
Virus rescue yields remain highly variable as shown by
yield variability between replicate transfections observed
also when using fusion. However, using fusion increased
yields which can help maximize the chances of rescuing
some constructs bearing relevant specific gene combina-
tions that make them difficult to rescue. We showed
here that it is possible to use up to 0.4 μg Env-
expressing DNA together with 0.6 μg of viral rescue
DNA in a 24-well plate format to optimize rescue effi-
ciency. We have found that these conditions improved
our ability to rescue some artificially reassorted strains
bearing specific gene combinations that we had previ-
ously not been able to rescue (unpublished results). The
difference in transfected DNA concentration between
24- and 6-well plate formats may explain the apparently
better virus yield observed in 24-well plates (Figure 3).
Cell fusion also allows virus rescue using only a fraction
of the amount of cloned viral genes that would normally
be required (Figure 2), a potential advantage when large
numbers of different constructs have to be made or
where some genes that are challenging to clone are
available in limiting quantity.
Cell fusion may enhance influenza virus rescue
through different mechanisms. We assumed that one
limiting factor was the requirement to successfully de-
liver eight separate plasmids to the same cell and antici-
pated that this could be enhanced by using cell fusion.
This is supported by the “4 + 4” and “7 + 1” experiment
results (Table 1) where the complement of plasmids was
deliberately incomplete. It is also supported by experi-
ments where the concentration of viral genes-carrying
plasmids was reduced to limiting levels, and where in-
clusion of the Env plasmid restored rescue efficiency
(Figure 2). Another hypothesis to account for enhanced
yield is that the MVV envelope protein from the host
cell might be incorporated into the primary progeny
virus envelope and facilitate the first round of infection
and hence amplification. However we believe the latter
to be unlikely as in order for viral RNPs to uncoat from
the matrix protein, they must be exposed to the acid en-
vironment of the endosome (reviewed in [30]). Direct
membrane fusion mediated via MVV Env is expected to
release viral cores directly into the cytoplasm without
prior acid exposure and thus non-infectious.
Other applications of the fusion methodology
In one experiment (Figure 4), we used the trypsin de-
pendence of the PR8 virus in cell culture to eliminatethe contribution of amplified virus to the overall yield.
Firstly, if it is possible to generate sufficient quantities of
primary progeny, one can examine the effect of lethal
mutations that may otherwise be unable to undergo
amplification (for example mutations in viral proteins or
genome RNA that impact on packaging). Viral progeny
can be analysed directly for genome complement and
ability to initiate a first round of infection. Our method
can generate about 104 p.f.u./mL of primary progeny in
a 24-well plate format, which could be sufficient for such
purposes.
A second application results from the potential offered
by fusing cells transfected with different complements of
virus segments. It may be possible to establish partial
infections in two cell populations, then allow fusion and
assay the completion of the virus life cycle. This would
be a novel tool studying interactions between different
segments during the packaging process and trafficking
of viral components.
Conclusion
The simple modification described herein has the poten-
tial to improve the efficiency of the virus rescue process




The virus rescue constructs were derived from the
RF483 plasmid which is modified from pHW2000 [18].
Both the Env-expressing and the inert B1 control plas-
mids included a T7 bacterial terminator [31] between
the CMV promoter and the insert to prevent transcrip-
tion in the bacteria. To insert this terminator, the two
complementary oligonucleotides T7eAS+: CAAGAGAA
AATGTAATCACACTGGCTCACCTTCGGGTGGGCC
TTTCTGCGTTTATAAGGAGACACTTTCCGGAGTA
CTGG and T7eAB-: TCGACCAGTACTCCGGAAAGT
GTCTCCTTATAAACGCAGAAAGGCCCACCCGAAG
GTGAGCCAGTGTGATTACATTTTCTCTTG (T7e ter-
minator sequence in bold) were annealed together in
10 mM TrisHCl pH 7.6 and 50 mM NaCl buffer in
a boiling temperature waterbath left to cool down
overnight. The annealed oligonucleotides formed a
double stranded insert bearing one cohesive and one
blunt end allowing its cloning into RF483 after this vec-
tor was digested with HpaI and SalI (New England Bio-
labs) as per enzyme manufacturer’s instructions.
Rescue protocol
On day −1, 5x105 HEK 293T/17 cells (hereafter re-
ferred to as 293T; ATCC #CRL-11268) were plated in
each well of a 6-well plate (9.5 cm2) in Dulbecco's
Modified Eagle Medium (DMEM) supplemented with
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amphotericin B (2.5 μg/mL), L-glutamine (10 mM), so-
dium pyruvate (1 mM) and fœtal calf serum (FCS)
(10% v/v). On the next day (day 0), each well was
transfected with 4 μg DNA total comprising equal pro-
portions of each of the eight viral plasmids combined
with a varying proportion of the Env-expressing or
empty control (B1) plasmid as indicated in the figure
legends. The B1 empty plasmid controls were included
to maintain a constant quantity of DNA and SV40 ori-
gins to control for non-specific effects on transfection
efficiency and origin replication. For transfections, ei-
ther 3 μL of FuGene (Roche) (Figures 2 and 4, Table 1)
or 3 μL of Lipofectamine LTX and 1 μL of Plus Re-
agent (Invitrogen) (Figure 3, Additional file 1 video 1
and Additional file 2 video 2) were used per μg of
DNA as per manufacturer's instructions. Cells were
incubated with the transfection mixture overnight at
37°C and 5% CO2 in 1 mL DMEM supplemented with
L-glutamine (10 mM), sodium pyruvate (1 mM) and FCS
(10% v/v). On the following day (day 1), the medium was
removed and cells were carefully washed with PBS before
being overlaid with 3 mL DMEM supplemented with peni-
cillin (100 U/mL), streptomycin (50 μg/mL), amphotericin
B (2.5 μg/mL), L-glutamine (10 mM), sodium pyruvate
(1 mM) and bovine serum albumin (BSA) (0.3% w/v) and
left to incubate for three more days.
Smaller scale assays used 24-well plates with 105 cells pla-
ted per well and transfected in a 0.5 mL medium volume
with 0.8 μg DNA total using 3 μL of transfection reagent
per μg of DNA. Cells were incubated overnight at 37°C and
5% CO2 in 500 μL medium. On day 1, the medium was
removed and cells were carefully washed with PBS before
being overlaid with 1 mL serum-free, BSA containing
medium as above and left to incubate for three more days.
Except where otherwise stated, trypsin was added to
1 μg/mL on day 3. On day 4, supernatants were har-
vested, aliquoted and frozen at −70°C. In order to
visualize cell fusion more easily, we included control
wells containing a GFP expressing plasmid with or with-
out the Env-expressing plasmid.
We first tested this approach on virus A/Puerto Rico/
8/34 (PR8), and then on a construct derived from the 8
gene segments of the low pathogenicity avian influenza
(LPAI) field sample A/mallard/Netherlands/10/99.
Figure 1 summarises the principle of the fusion ap-
proach in the context of the influenza A 8-plasmid res-
cue system. A video footage of the cell fusion process
was made using a BioStation IM-Q device (Nikon) and
can be accessed online.
Titration of viral yields
Viral yields in plaque forming units (p.f.u.) were titrated
by plaque formation assay in Madin-Darby Canine Kidney(MDCK) cells using the Avicel method with media supple-
mented with trypsin [32]. The inoculum was also incu-
bated with tryspin during the virus adsorption period.
Statistical analyses
Average viral yields between different treatments were
compared using 2-tailed Student's t-tests following
checks for normality and variance homogeneity using
Shapiro-Wilk and Levene tests, respectively. All tests
were conducted as implemented in the R statistical pro-
gram [33].
Additional files
Additional file 1: Video 1: 293T cells transfected with 0.4 μg of
GFP+ 0.4 μg of inert B1 plasmid. Cells were kept in FCS-containing
medium for the whole duration of the footage, which spans a 27-hour
period from 19 h to 46 h post transfection. More details are provided in
the article main text. Speed: x 4200.
Additional file 2: Video 2: 293T cells transfected with 0.4 μg of
GFP+ 0.4 μg Env plasmid. Cells were kept in FCS-containing medium
for the whole duration of the footage, which spans a 27-hour period
from 19 h to 46 h post transfection. The video shows a marked fusion
process (compare to Additional video 1), including visible cell-to-cell GFP
transfer, while cells keep dividing over time. More details are provided in
the article main text. Speed: x 4200.
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